“…To reduce such risks, it would probably be necessary to track viral variant emergence and to update siRNA desgin periodically, always administering combinations of siRNAs targeting distinct viral regions (hence: unlikely to mutate in the same variant) rather than a single This study Ambike et al, 2022Becker et al, 2022Chang et al, 2022Friedrich et al, 2022Sohrab et al, 2022bTolksdorf et al, 2021Idris et al, 2021Khaitov et al, 2021Nabiabad et al, 2022Niktab et al, 2021 . "High activity" was defined as a significant (p¡0.05) repression of viral RNA accumulation by 50% in infected cultured cells Khaitov et al, 2021 ;Tolksdorf et al, 2021 ;Sohrab et al, 2022b ;Sohrab et al, 2022a ;Chang et al, 2022 ;Becker et al, 2022 (and this study), or significant repression of viral plaque count by 50% Idris et al, 2021 ;Friedrich et al, 2022, or a measured IC 50 for cell infection inhibition being 10 nM Ambike et al, 2022. siRNAs have unclear activity when they were assessed in a siRNA mixture rather than individually Niktab et al, 2021 or when they were combined with an anti-hACE2 aptamer before administration to cultured cells Nabiabad et al, 2022 (gray arrows; also denoted by a question mark for the number of highly active siRNAs in column "High activity siRNAs / total"). SARS-CoV-2 ORF coordinates are from GenBank ACC # OP278726.1; mature proteins generated from the Orf1ab polyprotein are indicated by pink rectangles.…”